Posted on 25/11/2009 in Pharmaceutical Company Product News Lilly's antiplatelet medicine, Effient (prasugrel), has been added as a treatment option in two clinical guideline updates, the firm has revealed.
The first is for patients receiving percutaneous coronary intervention (PCI), while the second is for those with ST elevation myocardial infarction (STEMI) ? otherwise known as severe heart attack.
Effient was first approved by the Food and Drug Administration in June 2009 for lowering the risk of cardiac events in those suffering from acute coronary syndromes being treated with stenting and angioplasty.
LeRoy LeNarz, senior medical director of cardiovascular care at Lilly, stated: "By recommending Effient, these guidelines recognise an important new treatment for ACS-PCI patients, particularly for those with severe heart attacks who are at increased risk of suffering future cardiovascular events."
This news comes after Lilly collaborated on a film with the International Diabetes Fund, which was aired on World Diabetes Day and won an award at this year's Tribeca Festival.
Other news stories from 25/11/2009
Read more in the Zenopa News Archive
How this news is generated
|
